3-(3,4-dichlorophenyl)cyclohex-2-enone | 1251958-46-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(3,4-dichlorophenyl)cyclohex-2-enone
• 英文别名: 3-(3,4-dichlorophenyl)-2-cyclohexen-1-one；3-(3,4-Dichlorophenyl)cyclohex-2-en-1-one
• CAS: 1251958-46-9
• 化学式: C₁₂H₁₀Cl₂O
• 分子量: 241.117
• InChiKey: GRNRWXSADLMMJS-UHFFFAOYSA-N

物化性质

• 沸点：
  348.0±42.0 °C(Predicted)
• 密度：
  1.322±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-(3,4-dichlorophenyl)cyclohex-2-enone 在 氰化钾 、 氯化铵 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 以30%的产率得到1-(3,4-dichlorophenyl)-3-oxocyclohexanecarbonitrile
  参考文献：
  名称：

  WO2007/81857

  摘要：

  公开号：
• 作为产物：
  描述：

  1-(3,4-Dichlorophenyl)cyclohexanol 在 铜 、 Selectfluor 作用下， 以 乙腈 为溶剂， 反应 24.0h， 以53%的产率得到3-(3,4-dichlorophenyl)cyclohex-2-enone
  参考文献：
  名称：

  铜/Selectfluor 系统催化的叔环醇脱水氧化：获得 β-取代的 Cyclohex-2-enones、4-Arylcoumarins 和 Biaryls

  摘要：

  β-取代的环己-2-烯酮、4-芳基香豆素和联芳基的路线已经开发出来。这种方法涉及一锅 CuO/Selectfluor 催化的叔环醇脱水氧化。因此，通过使用 2 equiv。Selectfluor 在 25 °C 下，叔环己醇和氧杂苯并环己醇的脱水-氧化分别得到 β-取代的环己-2-烯酮和 4-芳基香豆素；而叔环己醇的脱水-氧化使用 2.5 当量得到联芳基化合物作为最终产物。Selectfluor 在 80 °C。

  DOI：

  10.1002/ejoc.201500610

文献信息

• Formation of Quaternary Chiral Centers by N-Heterocyclic Carbene-Cu-Catalyzed Asymmetric Conjugate Addition Reactions with Grignard Reagents on Trisubstituted Cyclic Enones
  作者：Stefan Kehrli、David Martin、Diane Rix、Marc Mauduit、Alexandre Alexakis

  DOI：10.1002/chem.201000471

  日期：2010.8.23

  The copper‐catalyzed conjugate addition of Grignard reagents to 3‐substituted cyclic enones allows the formation of all‐carbon chiral quaternary centers. We demonstrate in this article that N‐heterocyclic carbenes act as efficient chiral ligands for this transformation. High enantioselectivities (up to 96 % ee) could be obtained for a variety of substrates.

  将格氏试剂铜催化的共轭加成至3个取代的环烯酮上可以形成全碳的手性季中心。我们在本文中证明，N-杂环卡宾可作为这种转化的有效手性配体。对于各种底物，可以获得高对映选择性（最高96％  ee）。
• Cycloalkylamines as monoamine reuptake inhibitors
  申请人：Shao Liming

  公开号：US20070203111A1

  公开（公告）日：2007-08-30

  The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

  本发明涉及新型环己胺衍生物及其在中枢神经系统（CNS）疾病的治疗和/或预防中的应用，例如抑郁症、焦虑症、精神分裂症和睡眠障碍，以及它们的合成方法。本发明还涉及包含本发明化合物的制药组合物，以及抑制内源性单胺，如多巴胺、5-羟色胺和去甲肾上腺素从突触间隙中再摄取的方法和调节一个或多个单胺转运体的方法。
• CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS
  申请人：Shao Liming

  公开号：US20100190861A1

  公开（公告）日：2010-07-29

  The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

  本发明涉及新型环己基胺衍生物及其在治疗和/或预防中枢神经系统（CNS）疾病方面的应用，例如抑郁症，焦虑症，精神分裂症和睡眠障碍，以及它们的合成方法。本发明还涉及含有本发明化合物的制药组合物，以及抑制内源性单胺，如多巴胺，5-羟色胺和去甲肾上腺素从突触间隙中再摄取的方法，以及调节一个或多个单胺转运体的方法。
• Design, synthesis and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitor
  作者：Ikuo Fujimori、Tomoya Yukawa、Taku Kamei、Yoshihisa Nakada、Nobuki Sakauchi、Masami Yamada、Yusuke Ohba、Maiko Takiguchi、Masako Kuno、Izumi Kamo、Hideyuki Nakagawa、Teruki Hamada、Tomoko Igari、Teruaki Okuda、Satoshi Yamamoto、Tetsuya Tsukamoto、Yuji Ishichi、Hiroyuki Ueno

  DOI：10.1016/j.bmc.2015.05.017

  日期：2015.8

  Centrally acting noradrenaline reuptake inhibitor (NRI) is reportedly effective for patients with stress urinary incontinence (SUI) by increasing urethral closure in the clinical Phase IIa study with esreboxetine. Noradrenaline transporters are expressed in both central and peripheral nervous systems and the contribution of each site to efficacy has not been clarified. This report describes the development of a series of peripheral-selective 7-phenyl-1,4-oxazepane NRIs to investigate the contribution of the peripheral site to increasing urethral resistance in rats. (6S,7R)-1,4-Oxazepane derivative 7 exhibited noradrenaline transporter inhibition with high selectivity against inhibitions of serotonin and dopamine transporters. A replacement of hydroxyl with acetamide group contributed to enhancement of peripheral selectivity by increasing molecular polarity. Compound 12, N-[(6S,7R)-7-(3,4-dichlorophenyl)-1,4-oxazepan-6-yl]methyl}acetamide 0.5 fumarate, which showed effectively no brain penetration in rats, increased urethral resistance in a dose-dependent manner and exhibited a maximal effect on par with esreboxetine. These results demonstrate that the urethral resistance-increasing effects of NRI in rats are mainly caused by the inhibition of noradrenaline transporters in the peripheral sites. (C) 2015 Elsevier Ltd. All rights reserved.
• US8877975B2
  申请人：——

  公开号：US8877975B2

  公开（公告）日：2014-11-04